1.38
-0.06(-4.17%)
Currency In USD
| Previous Close | 1.44 |
| Open | 1.51 |
| Day High | 1.51 |
| Day Low | 1.34 |
| 52-Week High | 12.85 |
| 52-Week Low | 1.29 |
| Volume | 4.42M |
| Average Volume | 1.6M |
| Market Cap | 82.1M |
| PE | -0.46 |
| EPS | -3 |
| Moving Average 50 Days | 1.86 |
| Moving Average 200 Days | 2.3 |
| Change | -0.06 |
If you invested $1000 in Biomea Fusion, Inc. (BMEA) since IPO date, it would be worth $74.19 as of October 24, 2025 at a share price of $1.38. Whereas If you bought $1000 worth of Biomea Fusion, Inc. (BMEA) shares 3 years ago, it would be worth $150 as of October 24, 2025 at a share price of $1.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
GlobeNewswire Inc.
Oct 21, 2025 11:05 PM GMT
SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s SMID Biotech C-Suite Fireside Chat Series on Thur
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
GlobeNewswire Inc.
Oct 06, 2025 8:03 PM GMT
Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline, with a 1.8% placebo adjusted mea
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
SAN CARLOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on September 24, 2025, the compensation committee of